Dr. Daniel Olson, MD
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Area of expertise
Skin Cancer
Daniel Olson, MD has run 3 trials for Skin Cancer. Some of their research focus areas include:
Liposarcoma
Daniel Olson, MD has run 2 trials for Liposarcoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Chicago Comprehensive Cancer Center
UC Comprehensive Cancer Center At Silver Cross
Clinical Trials Daniel Olson, MD is currently running
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
Low-Dose Chemotherapy + Anti-Cancer Drug
for Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.
Recruiting
1 award
Phase 1
More about Daniel Olson, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Daniel Olson, MD has experience with
- Pembrolizumab
- TAC01-HER2
- Paclitaxel
- Nivolumab
- Doxorubicin
- Pegylated Liposomal Doxorubicin Hydrochloride
Breakdown of trials Daniel Olson, MD has run
Skin Cancer
Liposarcoma
Malignant Fibrous Histiocytoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Olson, MD specialize in?
Daniel Olson, MD focuses on Skin Cancer and Liposarcoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daniel Olson, MD currently recruiting for clinical trials?
Yes, Daniel Olson, MD is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Daniel Olson, MD has studied deeply?
Yes, Daniel Olson, MD has studied treatments such as Pembrolizumab, TAC01-HER2, Paclitaxel.
What is the best way to schedule an appointment with Daniel Olson, MD?
Apply for one of the trials that Daniel Olson, MD is conducting.
What is the office address of Daniel Olson, MD?
The office of Daniel Olson, MD is located at: University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.